Bioinformatics for NGS analysis
- المشتركون
- التغطية البريدية
- ER - نسبة المشاركة
جاري تحميل البيانات...
جاري تحميل البيانات...
Artificial intelligence (Al) is taking a transformative role in target identification and drug discovery. Today, Al algorithms can analyze vast, multi-modal datasets to identify drug targets, accelerate lead compound discovery, and optimize drug design. Al is being used by biotechnology companies around the world to compress timelines and improving clinical trial outcomes. Join Kimberly Robasky, Associate Director of Machine Learning / Al at Arrakis Therapeutics, as she discusses how to uncover the data-driven revolution in personalized medicine enabled by Al-driven drug development.
تسمح خطتك الحالية بتحليلات لما لا يزيد عن 5 قنوات. للحصول على المزيد، يُرجى اختيار خطة مختلفة.